E-viri
Recenzirano
Odprti dostop
-
Koekenbier, Eva L.; Fohse, Konstantin; van de Maat, Josephine S.; Oosterheert, Jan Jelrik; van Nieuwkoop, Cees; Hoogerwerf, Jacobien J.; Grobusch, Martin P.; van den Bosch, Maurice A.A.J.; van de Wijgert, Janneke H.H.; Netea, Mihai G.; Rosendaal, Frits R.; Bonten, Marc J.M.; Werkhoven, C.H. (Henri) van; Aardenburg-van Huisstede, Astrid; Ammerlaan, Heidi S.M.; Boersma, Willem G.; Bonten, Marc J.M.; van den Bosch, Maurice A.A.J.; Brinkman, Kees; Bruijning-Verhagen, Patricia C.J.; van Crevel, Reinout; Delsing, Corine; ten Doesschaten, Thijs; Dofferhoff, Anton S.M.; Duijkers, Ruud; Fohse, Konstantin; Grobusch, Martin P.; Groenwold, Rolf H.H.; de Haas, Corine; Hassing, Robert-Jan; de Hoog, Marieke L.A.; Hoogerwerf, Jacobien J.; Huijts, Susanne M.; van Hylckama-Vlieg, Astrid; Jong, Eefje; de Jong, Hanna K.; Knap, Martijn; Koekenbier, Eva L.; Koenders, Michael; Kouijzer, Ilse J.E.; Kramer, Henk; van de Laar, Roel; Lalmohamed, Arief; Lensen, Karel-Jan D.F.; Lijfering, Willem M.; van de Maat, Josephine S.; Magdelijns, Fabienne; Meek, Bob; Middelburg, Rutger A.; Moeniralam, Hazra S.; Mooijaart, Simon P.; van Munster, Barbara C.; Netea, Mihai G.; van Nieuwkoop, Cees; ten Oever, Jaap; Oosterheert, Jan Jelrik; Goossens, Marc Padros; Peters, Vincent; Postma, Douwe F.; Pouw, Niels; Reesink, Herre J.; de Regt, Marieke J.A.; van der Reijden, Anneli C.J.; Rosendaal, Frits R.; Schaakxs, R.; Slieker, Kitty; Slingerland, Robbert J.; van Sluis, Nicolette L.J.; Stehouwer, Coen D.A.; van de Veerdonk, Frank; Verbon, Annelies; van Werkhoven, C.H. (Henri); van de Wijgert, Janneke H.H.
Clinical microbiology and infection, 06/2023, Letnik: 29, Številka: 6Journal Article
To test whether Bacillus Calmette-Guérin (BCG) vaccination would reduce the incidence of COVID-19 and other respiratory tract infections (RTIs) in older adults with one or more comorbidities. Community-dwelling adults aged 60 years or older with one or more underlying comorbidities and no contraindications to BCG vaccination were randomized 1:1 to BCG or placebo vaccination and followed for 6 months. The primary endpoint was a self-reported, test-confirmed COVID-19 incidence. Secondary endpoints included COVID-19 hospital admissions and clinically relevant RTIs (i.e. RTIs including but not limited to COVID-19 requiring medical intervention). COVID-19 and clinically relevant RTI episodes were adjudicated. Incidences were compared using Fine-Gray regression, accounting for competing events. A total of 6112 participants with a median age of 69 years (interquartile range, 65–74) and median of 2 (interquartile range, 1–3) comorbidities were randomized to BCG (n = 3058) or placebo (n = 3054) vaccination. COVID-19 infections were reported by 129 BCG recipients compared to 115 placebo recipients hazard ratio (HR), 1.12; 95% CI, 0.87–1.44. COVID-19-related hospitalization occurred in 18 BCG and 21 placebo recipients (HR, 0.86; 95% CI, 0.46–1.61). During the study period, 13 BCG recipients died compared with 18 placebo recipients (HR, 0.71; 95% CI, 0.35–1.43), of which 11 deaths (35%) were COVID-19-related: six in the placebo group and five in the BCG group. Clinically relevant RTI was reported by 66 BCG and 72 placebo recipients (HR, 0.92; 95% CI, 0.66–1.28). BCG vaccination does not protect older adults with comorbidities against COVID-19, COVID-19 hospitalization, or clinically relevant RTIs.
